缺血性心肌病心力衰竭患者使用阿托伐他汀后对其血栓前状态的影响

The Effect of Atorvastatin on Prethrombotic State in Patients with Ischemic Cardiomyopathy and Heart Failure

目的观察缺血性心肌病(ICM)心力衰竭患者使用阿托伐他汀后对其血栓前状态(PTS)的影响。方法将于2015年9月至2016年9月入院接受治疗的200例ICM心力衰竭患者进行分组:分别为参照组与治疗组,每组患者100例。常规治疗方法应用于参照组患者中,阿托伐他汀应用于治疗组患者中,对2组患者治疗前后的血小板P选择素、纤维蛋白原(Fbg)、纤溶酶原激活抑制物1(PAI-1)和D二聚体(D-D)变化状况进行分析比较,并对比观察2组患者的不良反应发生状况和临床疗效状况。结果 2组患者治疗前的血小板P选择素、Fbg、PAI-1以及D-D的变化状况无明显差异,(P>0.05);治疗后,2组患者的血小板P选择素、Fbg、PAI-1和D-D状况均得到改善,且治疗组患者的改善状况优于参照组患者(P<0.05)。治疗组患者的不良反应发生率高于参照组患者,但差异无统计学的意义(P>0.05);治疗组患者的总有效率高于参照组患者(P<0.05)。结论在ICM心力衰竭患者中应用阿托伐他汀后,可降低血栓事件的发生,且不良反应少,有效率高。

Objective To observe the effect of atorvastatin on the prethrombotic state（PTS） in patients with ischemic cardiomyopathy （ICM）heart failure. Methods 200 patients with ICM heart failure who were enrolled from September 2015 to September 2016 were enrolled in this study ： 100 patients in each group were treated with reference and treatment. The levels of platelet P- selectin, fibrinogen （Fbg） , plasminogen activator inhibitor- 1 （PAI） in the treatment group were significantly higher than those in the control group （ P 〈 0. 05 ）. The patients were treated with atorvastatin in the treatment group-1 ）and D-dimer （D-D）were analyzed and compared, and the adverse reaction status and clinical efficacy of the two groups were observed and compared. Results 2 groups of patients before treatment, the platelet P selectin, Fbg, there was no significant difference between PAI- 1 and D- D changes （ P 〉 0. 05 ） ; after treatment, the 2 groups of patients with platelet P selectin, Fbg, PAI-1 and D-D status were improved, and the treatment group were improved better than the control group patients （ P 〈 0. 05 ）. The adverse reaction of patients in the treatment group was higher than that of the reference group of patients, but the difference was not statistically significant （ P 〉 0. 05 ） ; the total effective rate of treatment group than the control group patients （ P 〈 0. 05 ）. Conclusion ICM heart The use of atorvastatin in patients with failure can reduce the incidence of thrombotic events, with less adverse reactions and high efficiency.